IDO1 and neoplasm: Previous studies have shown that IDO1 can reduce tryptophan levels and increase tryptophan metabolite levels, primarily kynurenine, in the tumor microenvironment by modulating the tryptophan metabolic pathway, resulting in dysfunction and diminished antitumor effects of CD8 + T cells [57, 58].